LY 255283

structure given in UD; leukotriene B4 antagonist

Also Known As:

(1-(5-ethyl-2-hydroxy-4-(6-methyl-6-(1H-tetrazol-5-yl)heptyloxy)phenyl)ethanone); LY-255283; LY255283; Ethanone, 1-(5-ethyl-2-hydroxy-4-((6-methyl-6-(2H-tetrazol-5-yl)heptyl)oxy)phenyl)-

Networked: 15 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Tetrazoles: 14
      - LY 255283: 15

Experts

1.	Kim, Jae-Hong: 4 articles (01/2019 - 04/2010)
2.	Kim, Cheolmin: 2 articles (09/2010 - 04/2010)
3.	Kim, Eun-Young: 2 articles (09/2010 - 04/2010)
4.	Seo, Ji-Min: 2 articles (09/2010 - 04/2010)
5.	Chan, Su Jing: 1 article (01/2020)
6.	De Foo, Chuan: 1 article (01/2020)
7.	Ng, Geelyn J L: 1 article (01/2020)
8.	Ng, Mary P E: 1 article (01/2020)
9.	Seet, Raymond C S: 1 article (01/2020)
10.	Wong, Peter T-H: 1 article (01/2020)

Related Diseases

1.	Sunburn 04/01/2010 - "Topical treatment of mouse epidermal skin with LY255283 gave significant protection against UVB-induced sunburn-associated apoptotic damage. "
2.	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 12/01/1993 - "To evaluate the hypothesis that treatment with LY255283, a novel leukotriene B4-receptor antagonist, is beneficial in an animal model of the adult respiratory distress syndrome induced by endotoxin. "
3.	Eosinophilia 12/15/1998 - "5-Oxo-ETE-induced eosinophilia was unaffected by the LTB4 and PAF antagonists LY255283 and WEB 2170, respectively. " 01/01/1991 - "The lung eosinophilia in the rat was prevented by two structurally unrelated leukotriene B4 (LTB4) antagonists, U-75302 and Ly255283. " 01/01/1991 - "Effect of the selective leukotriene B4 antagonists U-75302 and Ly255283 on bronchoalveolar eosinophilia induced by inhalation of leukotriene B4 or allergen in brown-Norway rats."
4.	Infarction (Infarctions) 04/01/1990 - "Resultant infarct sizes were 43 +/- 5% of the left ventricle placed at risk in control dogs and 32 +/- 5% in dogs given LY255283; this difference was not statistically significant. " 01/01/2020 - "Conversely, administration of the 5-LOX-activating protein (FLAP) inhibitor BAY-X1005 or B-leukotriene receptor (BLTR) antagonist LY255283 decreased the infarct volume by a similar extent. "
5.	Hypotension (Low Blood Pressure) 08/01/1991 - "The LTB4-receptor antagonist LY255283 (10 mg/kg bolus i.v., 10 min before endotoxin followed by a 5 mg/kg bolus i.v. 30 min postendotoxin) completely inhibited endotoxin-induced systemic hypotension and partially attenuated endotoxin-induced hemoconcentration from 15 min to 90 min postendotoxin (P less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)" 12/01/1993 - "Treatment with LY255283 significantly (p < .05) ameliorated lipopolysaccharide-induced systemic arterial hypotension, pulmonary arterial hypertension, and arterial hypoxemia. "

Related Drugs and Biologics

1.	Endotoxins
2.	Leukotrienes
3.	Leukotriene B4
4.	Small Interfering RNA (siRNA)
5.	Leukotriene B4 Receptors (Leukotriene B4 Receptor)
6.	Lipopolysaccharides
7.	U 75302
8.	Cyclin D1
9.	Leukotriene Receptors (Leukotriene Receptor)
10.	Estrogen Receptors